FIL Lima 2026 ¡Hasta 50% OFF AQUÍ!  Ver más

Enviar a
CERCADO DE LIMA, Lima
0
  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional

Selecciona tu país

América

Europa

Resto del mundo

portada Off the Scales: The Inside Story of Ozempic and the Race to Cure Obesity (en Inglés)
Formato
Libro Físico
Idioma
Inglés
N° páginas
320
Encuadernación
Tapa Dura
ISBN13
9781250389060

Off the Scales: The Inside Story of Ozempic and the Race to Cure Obesity (en Inglés)

Aimee Donnellan (Autor) · St. Martin's Press · Tapa Dura

Off the Scales: The Inside Story of Ozempic and the Race to Cure Obesity (en Inglés) - Aimee Donnellan

Más barato Libro Nuevo Importado
Envío: 17 a 23 días háb.
S/ 230,12S/ 103,55
-55%
Más rápido Libro Nuevo Importado
Envío: 12 a 19 días háb.
S/ 241,74S/ 108,78
-55%
Libro UsadoBuen Estado Importado
Envío: 14 a 20 días háb.
S/ 54,76
Costos de importación incluídos en el precio ✅
Libro Nuevo Más barato

Quedan 15 unidades

S/ 103,55
Llega entre el 20 Ago y el 31 Ago a CERCADO DE LIMA, Lima. Seleccionar ubicación

Reseña del libro "Off the Scales: The Inside Story of Ozempic and the Race to Cure Obesity (en Inglés)"

The inside story of the creation of Ozempic and its revolutionary impact on public health.A "cure" for obesity has long been the holy grail for the pharmaceutical industry, one that seemed unattainable until recent breakthroughs in type 2 diabetes research led to the development of Ozempic, a weight loss medication that activates a hormone in the stomach called GLP-1, making people feel fuller for longer. The treatment is so effective that it is already disrupting many industries--from healthcare to fast food to fashion--and it has quickly made its creator, Denmark's Novo Nordisk, the most valuable company in Europe. But the impact of GLP-1s goes far beyond billion-dollar profits; a true long-term cure for obesity could save 40 percent of American adults from dangerous, preventable illnesses. And as more potential benefits emerge, one question looms in the minds of investors, healthcare workers, and politicians: Are these drugs too good to be true? In Off the Scales, Reuters journalist Aimee Donnellan illuminates the history of a medical breakthrough that is poised to change the world, while raising difficult social questions about inequality and morality. Through original reporting and rigorous research, she forecasts the future of GLP-1s and examines what their explosive popularity tells us about our ideals of beauty and the lengths to which people will go in order to become thin. Along the way, Donnellan profiles the scientist whose contributions to the discovery of GLP-1 were overlooked, documents her fight for recognition while her colleagues were thrust into the limelight, and offers new insights into the ways that the food and beauty industries made billions while promoting unhealthy and unrealistic body image standards and accelerating the obesity crisis. She also provides firsthand accounts of several early Ozempic users and the transformative effect the drug has had on their weight loss journeys. Off the Scales is an informative and entertaining study of the unexpected consequences of finally getting what we've wanted for so long.

Opiniones del libro

Preguntas frecuentes sobre el libro

Todos los libros de nuestro catálogo son Originales.
El libro está escrito en Inglés.
La encuadernación de esta edición es Tapa Dura.

Preguntas y respuestas sobre el libro

¿Tienes una pregunta sobre el libro? Inicia sesión para poder agregar tu propia pregunta.

Opiniones sobre Buscalibre

Ver más opiniones de clientes